Regulatory Updates
Aug 30, 2026•1 min read
FDA Approves Nabumetone (ANDA078420) for Prescription Oral Tablets
The FDA has approved ANDA078420 for Nabumetone tablets (500 mg and 750 mg) marketed by ScieGen Pharmaceuticals, adding a new oral NSAID to the prescription market.
Regulatory Updates
Aug 30, 2026•1 min read
FDA Approves ANDA078671 for NABUMETONE Oral Tablets
FDA granted approval for ANDA078671 covering prescription NABUMETONE tablets (500 mg and 750 mg) from sponsor Invagen Pharms, manufactured by Exelan Pharmaceuticals and Cipla USA.